natgillin/translations-raw huggingface dataset:
In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
Pri psih se našteti neželeni učinki pretežno pojavijo v prvem tednu zdravljenja, so večinoma prehodni in po končanem zdravljenju minejo, vendar so lahko v zelo redkih primerih tudi resni ali smrtno nevarni.
In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.
Pri psih se našteti neţeleni škodljivi učinki preteţno pojavijo v prvem tednu zdravljenja, so večinoma prehodni in po končanem zdravljenju minejo, vendar so lahko v zelo redkih primerih tudi resni ali smrtno nevarni.
In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.
Pri psih se našteti neželeni škodljivi učinki pretežno pojavijo v prvem tednu zdravljenja, so večinoma prehodni in po končanem zdravljenju minejo, vendar so lahko v zelo redkih primerih tudi resni ali smrtno nevarni.
In dogs, when cefovecin was administered as a single subcutaneous dose of 8 mg/kg bodyweight, absorption was rapid and extensive; peak plasma concentration at 6 hours was 120 g/ml and bioavailability approximately 99 %.
Po enkratnem subkutanem dajanju odmerka 8 mg/kg telesne teže pri psih, se je cefovecin hitro in obsežno resorbiral; vrh plazemske koncentracije po 6-ih urah je bil 120 µg/ml in biorazpoložljivost približno 99 %.
In dogs:
Psi:
In dogs: Moderate swelling at the implant site may be observed for 14 days.
Pri psih: Zmerno otekanje mesta implantacije lahko opažamo 14 dni.
In dolutegravir Phase III studies patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN).
V študijah faze III z dolutegravirjem so bolniki s sočasno okužbo z virusom hepatitisa B in/ali C smeli biti vključeni v študijo pod pogojem, da njihove izhodiščne vrednosti jetrnih testov niso presegle petkratne zgornje meje normale (ULN – upper limit of normal).
In dose-finding trials involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed small cell lung cancer, the dose limiting toxicity of topotecan monotherapy was found to be haematological.
V preskušanjih za določitev odmerka, v katerih je sodelovalo 523 bolnic s ponovitvijo (relapsom) raka jajčnikov in 631 bolnikov s ponovitvijo drobnoceličnega pljučnega raka, so ugotovili, da je pri monoterapiji s topotekanom toksičnost, ki omejuje njegov odmerek, hematološka.
In double blind and open-label clinical trials in 4,149 patients treated with abatacept during
V dvojno slepih in odprtih kliničnih preskušanjih pri 4.149 bolnikih, ki so se z abataceptom zdravili
In drinking water
V vodo za pitje
In drinking water use
Za dajanje v vodo za pitje.
In drinking water use
Za uporabo v pitni vodi
In drinking water use
Za uporabo v vodi za pitje.
In drinking water use, nebulisation use, oculonasal use
V vodi za pitje, z razprševanjem ali okulonazalno
In ducks:
Pri racah:
In DUET-1 and DUET-2, the presence at baseline of 3 or more of the following mutations: V90I, A98G, L100I, K101E, K101P, V106I, V179D, V179F, Y181C, Y181I, Y181V, G190A and G190S,
V študijah DUET-1 in DUET-2 je bila navzočnost 3 ali več mutacij izmed V90I, A98G, L100I, K101E, K101P, V106I, V179D, V179F, Y181C, Y181I, Y181V, G190A ali G190S (RAM zdravila
In duplicate prior to therapy.
dvakrat pred začetkom zdravljenja;
In each case the product is packed in a clam-shell-like child resistant container.
Zdravilo je v obeh primerih pakirano v školjki podobnem vsebniku z zaporko, varno za otroke.
In each case, these antibodies were non-neutralizing and did not interfere with the response to stimulation or the normal physiologic responses of the Hypothalamic-Pituitary-Ovarian (HPO) axis.
Pri nobeni ženski ta telesa niso bila nevtralizirajoča in niso vplivala na odziv na stimulacijo ali na normalne fiziološke odzive hipotalamo- hipofizno-ovarijske osi.
In each Member State where Aripiprazole Accord for the treatment up to 12 weeks of moderate to severe manic episode in Bipolar I Disorder in adolescents aged 13 years and older is launched the Marketing Authorisation Holder (MAH) shall agree an educational programme with the National Competent Authority.
V vsaki državi članici, kjer se bo zdravilo Aripiprazol Accord uporabljalo za novo indikacijo, to je za zdravljenje zmernih do hudih maničnih epizod pri bipolarni motnji I pri mladostnikih, starih 13 let in več v trajanju do 12 tednov, mora imetnik dovoljenja za promet z nacionalnim pristojnim organom dogovoriti izobraževalni program.
In each Member State where Aripiprazole Mylan Pharma for the treatment up to 12 weeks of moderate to severe manic episode in Bipolar I Disorder in adolescents aged 13 years and older is launched the Marketing Authorisation Holder (MAH) shall agree an educational programme with the National Competent Authority.
V vsaki državi članici, kjer se bo zdravilo Aripiprazol Mylan Pharma uporabljalo za zdravljenje zmernih do hudih maničnih epizod pri bipolarni motnji I pri mladostnikih, starih 13 let in več v trajanju do 12 tednov, mora imetnik dovoljenja za promet z nacionalnim pristojnim organom dogovoriti izobraževalni program.
In each Member State where Aripiprazole Sandoz for the treatment up to 12 weeks of moderate to severe manic episode in Bipolar I Disorder in adolescents aged 13 years and older is launched the Marketing Authorisation Holder (MAH) shall agree an educational programme with the National Competent Authority.
V vsaki državi članici, kjer se bo zdravilo Aripiprazol Sandoz uporabljalo za zdravljenje zmernih do hudih maničnih epizod pri bipolarni motnji I pri mladostnikih, starih 13 let in več v trajanju do 12 tednov, mora imetnik dovoljenja za promet z nacionalnim pristojnim organom dogovoriti izobraževalni program.
In each Member State, the Marketing Authorisation Holder (MAH) shall agree the content and format of the educational material with the national competent authority and implement it prior to launch.
Imetnik dovoljenja za promet z zdravilom se bo v vsaki državi članici dogovoril za vsebino in obliko izobraževalnega gradiva z nacionalnim pristojnim organom in ga uvedel pred začetkom prodaje.
In each of the clinical studies performed in the treatment of VOD, over 50% of patients were under the age of 18 years.
V vseh kliničnih študijah, opravljenih pri zdravljenju VOB, je bilo več kot 50 % bolnikov starih manj kot 18 let.
In each of the phase III studies and the pooled analysis, mean retinal thickness was significantly less, and the mean reduction from baseline was significantly greater, with OZURDEX (-207.9 microns) compared to sham (-95.0 microns) at day 90 (p < 0.001, pooled data).
V obeh študijah 3. faze in analizi zbranih podatkov je bila srednja debelina mrežnice pomembno manjša, srednje zmanjšanje od izhodiščne vrednosti pa pomembno večje pri zdravilu OZURDEX (–207,9 mikrona) kot pri placebu (–95,0 mikrona) na 90. dan (p < 0,001, zbrani podatki).
In each of two randomised, placebo-controlled trials, PROWESS and ADDRESS (see section 5.1), 28- day and in-hospital mortality were higher in patients treated with drotrecogin alfa (activated) compared to placebo for the sub-population of patients with single organ dysfunction and recent surgery (n=98 in PROWESS and n=636 in ADDRESS).
V vsakem od dveh randomiziranih s placebom kontroliranih preskušanj, PROWESS in ADDRESS (glejte poglavje 5.1), sta bili 28-dnevna umrljivost in umrljivost v času hospitalizacije višji pri bolnikih, zdravljenih z drotrekoginom alfa (aktiviranim), v primerjavi s placebom, pri podskupini bolnikov z okvarjenim delovanjem enega organa in nedavnim operacijskim posegom (n = 98 v preskušanju PROWESS in n = 636 v preskušanju ADDRESS).
In each pack
Vsebina pakiranja:
In each study around 300 suckling piglets were vaccinated with Porcilis PCV M Hyo and a second group of around 300 suckling piglets received a dummy injection.
V vsaki študiji so približno 300 sesnih pujskov cepili s cepivom Porcilis PCV M Hyo, približno 300 sesnim pujskom pa so injicirali zdravilo brez zdravilne učinkovine (placebo).
In each treatment group, there was a slightly greater percentage of subjects in the 2+ lines of prior systemic therapy for advanced disease (58 % and 55 % respectively for placebo and pazopanib treatment arms) compared with 0 or 1 lines of prior systemic therapy (42 % and 45 % respectively for placebo and pazopanib treatment arms).
V vsaki terapevtski skupini je bil rahlo večji odstotek preiskovancev z 2 ali več linijami predhodnega sistemskega zdravljenja napredovale bolezni (58 % v skupini s placebom, 55 % v skupini s pazopanibom) kot z 0 ali 1 linijo predhodnega sistemskega zdravljenja (42 % v skupini s placebom in 45 % v skupini s pazopanibom).
In each trial, the effects were sustained over the 24 hour dosing interval.
V vsakem preskušanju so učinki zdravila trajali ves čas 24- urnega intervala odmerjanja.
In early and advanced Parkinson’s disease, efficacy of pramipexole in controlled clinical trials was maintained for approximately six months.
Pri bolnikih z zgodnjo in napredovalo Parkinsonovo boleznijo se je učinkovitost pramipeksola v približno 6-mesečnih nadzorovanih kliničnih preskušanjih ohranjala.
In early and advanced Parkinson’s disease, efficacy of pramipexole in controlled clinical trials was maintained for approximately six months.
Pri bolnikih z zgodnjo in napredovalo Parkinsonovo boleznijo, je bila učinkovitost pramipeksola v kontroliranih kliničnih preskušanjih vzdrževana približno šest mesecev.
In early and advanced Parkinson’s disease, efficacy of pramipexole in the controlled clinical trials was maintained for approximately six months.
V kontroliranih kliničnih preizkušanjih je učinek pramipeksola pri bolnikih z zgodnjo in napredovalo Parkinsonovo boleznijo trajal približno šest mesecev.
In EGFR mutation-positive patients, significantly more IRESSA-treated patients experienced an improvement in quality of life and lung cancer symptoms vs carboplatin/paclitaxel (see Table 4).
Med bolniki s pozitivno mutacijo EGFR so se kakovost življenja in simptomi pljučnega raka izboljšali značilno več bolnikom, zdravljenim z zdravilom IRESSA, kot bolnikom, zdravljenim s karboplatinom/paklitakselom (glejte preglednico 4).
In eight clinical studies, the overall rates of adverse reactions after a second dose of ProQuad were generally similar to, or lower than, those seen with the first dose.
V osmih kliničnih študijah je bil skupni delež neželenih učinkov po drugem odmerku cepiva ProQuad na splošno podoben ali manjši od tistega po prvem odmerku.
In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study).
V kliničnem preskušanju Einstein DVT so preučevali učinkovitost in varnost zdravila Xarelto pri zdravljenju GVT in preprečevanju ponovne GVT in PE (bolniki, ki so imeli simptomatsko PE, so bili izključeni iz tega preskušanja), pri 3.449 bolnikih z akutno GVT.
In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent DVT and PE.
V kliničnem preskušanju Einstein Extension so preučevali učinkovitost in varnost zdravila Xarelto pri preprečevanju ponovne GVT in PE pri 1.197 bolnikih z GVT ali PE.
In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE.
V kliničnem preskušanju Einstein PE so preučevali učinkovitost in varnost zdravila Xarelto pri zdravljenju PE in preprečevanju ponovne GVT in PE pri 4.832 bolnikih z akutno PE.
In either case it should be confirmed by a blood test that AUBAGIO has been sufficiently removed from your body and you need confirmation from your treating physician that the blood level of AUBAGIO is low enough to allow you to become pregnant.
V vsakem primeru je treba s krvno preiskavo potrditi, da se je zdravilo AUBAGIO zadostno odstranilo iz vašega telesa, zato mora vaš lečeči zdravnik potrditi, da so ravni zdravila AUBAGIO v vaši krvi dovolj nizke, da lahko zanosite.
In either case it should be confirmed by a blood test that Leflunomide Winthrop has been sufficiently removed from your body and you should then wait for at least another month before you become pregnant.
V obeh primerih je treba s krvno preiskavo potrditi, da se je zdravilo Leflunomid Winthrop dovolj odstranilo iz telesa, potem pa morate počakati vsaj še en mesec, preden zanosite.
In either case the A771726 plasmaconcentration is then measured for thefirst time.
V obeh primerih se nato prvič izmeri plazemska koncentracija A771726.
In elderly healthy subjects (aged ≥65 years; n=20), the exposure to vortioxetine increased up to 27% (Cmax and AUC) compared to young healthy control subjects (aged ≤45 years) after multiple doses of 10 mg/day.
Pri starejših zdravih osebah (starih ≥ 65 let; n=20) se je izpostavljenost povečala do 27 % (Cmax in AUC) v primerjavi z mladimi zdravimi kontroliranimi osebami (starimi ≤ 45 let) po večkratnih odmerkih 10 mg/dan.
In elderly healthy subjects, pharmacokinetics of fondaparinux are linear in the range of 2 to 8 mg by subcutaneous route.
Pri starejših osebah je farmakokinetika fondaparinuksa po subkutani uporabi odmerkov od 2 do 8 mg linearna.
In elderly healthy subjects, pharmacokinetics of fondaparinux are linear in the range of 2 to 8 mg by subcutaneous route.
Pri zdravih starejših osebah je farmakokinetika fondaparinuksa po subkutani uporabi odmerkov od 2 do 8 mg linearna.
In elderly patients (> 75 years) there is limited clinical experience.
Z uporabo pri starejših bolnikih (> 75 let) je malo kliničnih izkušenj.
In elderly patients a dose reduction may be necessary.
Pri starejših bolnikih bo morda potrebno zmanjšanje odmerka.
In elderly patients the pharmacokinetic profile of lamivudine suggests that normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min (see section 4.2).
Farmakokinetični profil lamivudina pri starejših bolnikih kaže, da pojemanje ledvične funkcije med normalnim staranjem nima klinično pomembnega učinka na izpostavljenost lamivudinu, razen pri bolnikih, ki imajo očistek kreatinina < 50 ml/min (glejte poglavje 4.2).
In elderly patients, the time taken to fall asleep was often decreased with Zerene 5 mg and was always decreased with Zerene 10 mg, when they were compared with placebo in the two-week studies.
V primerjavi s placebom je bil v dvotedenskih študijah pri starejših bolnikih, ki so jemali zdravilo Zerene v odmerku 5 mg, čas, potreben, da so zaspali, pogosto krajši, pri jemanju 10-miligramskih odmerkov pa je bil vedno krajši.
In elderly people with dementia, a small increase in the number of deaths has been reported for patients taking medicines for schizophrenia compared with those not receiving these medicines.
Pri starostnikih z demenco, ki so prejemali zdravila za zdravljenje shizofrenije, so poročali o rahlem povečanju števila smrtnih primerov v primerjavi z bolniki, ki niso prejemali teh zdravil.
In elderly people, single doses also met the CHMP’s criteria, except for in the small number of patients aged over 80 years who did not have any protection against the virus at the start of the study.
Pri starejših osebah so enojni odmerki cepiva prav tako izpolnili merila odbora CHMP, razen pri manjšem številu bolnikov, starejših od 80 let, ki na začetku študije niso imeli razvite zaščite pred virusom.
In eltrombopag clinical trials in ITP thromboembolic events were observed at low and normal platelet counts.
V kliničnih preskušanjih z eltrombopagom pri ITP so o pojavu trombemboličnih dogodkov poročali tudi pri bolnikih, ki so imeli nizko in normalno število trombocitov.
In embryo-fetal and developmental toxicity studies (rats and rabbits) with dextromethorphan hydrobromide/quinidine sulfate, abnormalities were observed at mid and high dose with reduced ossification from the lowest dose in rats which is approximately 1 and 50 times the human dose of 30/18 mg/day on a mg/m2 basis, respectively.
V študijah embriofetalne in razvojne toksičnosti (pri podganah in kuncih) z dekstrometorfanijevim bromidom/kinidinijevim sulfatom so opazili anomalije pri srednjem in visokem odmerku z zmanjšano osifikacijo od najnižjega odmerka pri podganah, kar je približno 1-kratnik in 50-kratnik odmerka za človeka 30/18 mg/dan na podlagi mg/m2.
In embryo/foetal developmental studies abortion, but no developmental effects were seen in mice and rats at doses that were at least 860-times or 1700-times higher than the dose in humans, respectively.
V razvojnih raziskavah na mišjih in podganjih embrijih/fetusih so zabeležili abortuse, vplivov na embrio-fetalni razvoj pri odmerkih, ki so bili 860- oz 1700-krat večji od odmerka pri ljudeh, niso opazili.
In endemic areas regular monthly application will prevent angiostrongylosis and patent infection with
V endemičnih področjih bomo z rednim mesečnim nanosom zdravila preprečevali okužbe z
In endemic areas regular monthly applications will prevent angiostrongylosis and patent infection with
V endemičnih področjih bomo z rednim mesečnim dajanjem zdravila preprečevali okužbe z
in endoscopic procedures (procedures that use an endoscope for viewing internal organs) or keyhole surgery
pri endoskopskih posegih (posegih, pri katerih se za ogled notranjih organov uporablja endoskop) ali pri laparoskopskih posegih
In ENGAGE AF-TIMI 48 study in NVAF, efficacy and safety results were similar for subjects with and without concomitant amiodarone use.
V študiji ENGAGE AF-TIMI 48 pri NVAF so bili rezultati učinkovitosti in varnosti podobni pri preiskovancih s sočasno uporabo amiodarona in pri tistih brez nje.
In EOD4 (“superscan”) patients, thrombocytopenia (all grades) was reported in 19.6% of patients treated with Xofigo and in 6.7% of patients receiving placebo.
Pri bolnikih z difuznim intenzivnim kopičenjem po kosteh (EOD4, t. i. “superscan”) so o trombocitopeniji (vseh stopenj) poročali pri 19,6 % bolnikov, zdravljenih z zdravilom Xofigo in pri 6,7 % bolnikov, ki so prejemali placebo.
In epilepsy, the benefits of Pregabalin Pfizer were evaluated in 3 studies involving 1,000 patients that looked at how much it reduced the number of seizures patients had after 11 to 12 weeks.
Pri epilepsiji so koristi zdravila Pregabalin Pfizer ocenjevali v treh študijah, v katerih je sodelovalo
In Europe, it is estimated that these are responsible for about 54% to 84% of invasive infections (infections that have spread into the body) in infants and children under the age of two years, and for about 62% to 83% of invasive infections in children aged between two and five years.
Po evropskih ocenah so ti serotipi odgovorni za približno 54 % do 84 % invazivnih okužb (okužb, ki so se razširile po telesu) dojenčkov in otrok, ki so mlajši od dveh let, in približno 62 % do 83 % invazivnih okužb otrok, ki so stari med dvema in pet let.
In Europe, it is estimated that these are responsible for about 56 to 90% of the cases of invasive disease caused by S. pneumoniae in children under the age of five years.
V Evropi se ocenjuje, da so ti odgovorni za približno 56 do 90 % primerov invazivne bolezni pri otrocih, mlajših od pet let.
In Europe, it is estimated that these are responsible for between 73 and 100% of the cases of invasive disease in children under the age of five years, and at least 50 – 76% of the cases of invasive disease in adults, depending on the country.
Po ocenah so ti serotipi v Evropi odgovorni za približno 73 do 100 % invazivnih okužb pri otrocih, mlajših od pet let, in za najmanj 50 do 76 % primerov invazivne bolezni pri odraslih, odvisno od države.
In evaluating patients for infections, the patient’s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be considered.
Pri pregledovanju bolnikov glede okužb moramo upoštevati bolnikovo tveganje za relevantne oportunistične okužbe (npr. izpostavljenost endemičnim mikozam).
In every 4-week cycle a dose of dexamethasone should be taken on the first day of each week only.
V vsakem 4-tedenskem ciklu morate vzeti odmerek deksametazona samo prvega dne vsakega tedna.
In every 4-week cycle, Imnovid should be taken once a day for 3 weeks, followed by a week off.
V vsakem 4-tedenskem ciklu jemljite zdravilo Imnovid 3 tedne po enkrat na dan, sledi naj en teden brez zdravljenja.
In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
Izjemoma se lahko pojavi preobčutljivostna reakcija, ki jo je treba ustrezno simptomatično zdraviti
In exceptional circumstances, where prolonged systemic fusidic acid is needed e.g for the treatment of severe infections, the need for co-administration of pravastatin and fusidic acid should only be considered on a case by case basis and under close medical supervision.
V izjemnih okoliščinah, ko je potrebno podaljšano sistemsko zdravljenje s fusidno kislino, npr. za zdravljenje hudih okužb, je sočasna uporaba pravastatina in fusidne kisline upoštevna le v posameznih primerih in pod strogim zdravniškim nadzorom.
In excess, VEGF-A causes abnormal blood vessel growth and swelling in the eye which can lead to impairment of vision in diseases like AMD, PM, DME or RVO.
Kadar je beljakovine VEGF-A preveč, povzroča rast nenormalnih krvnih žil in otekanje v očesu, kar lahko povzroči okvaro vida pri boleznih, kot so starostna degeneracija makule, degenerativna kratkovidnost, diabetični makularni edem in zapora mrežnične vene.
In experimental studies Zinforo was shown to have activity against certain bacteria against which other antibiotics belonging to the beta-lactam class do not work (methicillin resistant Staphylococcus aureus (MRSA) and penicillin non-susceptible Streptococcus pneumoniae (PNSP)).
V poskusnih študijah je zdravilo Zinforo izkazalo delovanje na določene bakterije, na katere drugi antibiotiki iz skupine betalaktamov ne delujejo (na Staphylococcus aureus, odporno proti meticilinu (MRSA), in Streptococcus pneumoniae, neobčutljivo na penicilin (PNSP)).
In exploratory pharmacokinetic adverse event analyses, higher exposure to nintedanib tended to be associated with liver enzyme elevations, but not with gastrointestinal adverse events.
V eksploracijskih farmakokinetičnih analizah neželenih učinkov se je pri večji izpostavljenosti nintedanibu kazal trend k povezavi s povečanjem vrednosti jetrnih encimov, ne pa tudi z neželenimi učinki v prebavilih.
In extensive field testing no interactions between the veterinary medicinal product and routinely used veterinary medicinal products or medical or surgical procedures were observed.
Pri testiranju na terenu niso opazili nikakršnega medsebojnega delovanja med Strongholdom in drugimi rutinsko uporabljanimi zdravili.
In extremely rare cases the following side effects have been reported with hepatitis B vaccine.
V zelo redkih primerih so bili v povezavi s cepivom proti hepatitisu B poročani naslednji neželeni učinki.
In extremely rare cases, allergic reactions mimicking serum sickness, paralysis, neuropathy, neuritis, hypotension, vasculitis, lichen planus, erythema multiforme, arthritis, muscular weakness, Guillain- Barré syndrome, encephalopathy, encephalitis and meningitis have been reported.
V izjemno redkih primerih so poročali o alergijski reakciji podobni serumski bolezni, paralizi, nevropatiji, nevritisu, hipotenziji, vaskulitisu, lichen planusu, multiformnem eritemu, artritisu, mišični šibkosti, Guillain-Barréjevem sindromu, encefalopatiji, encefalitisu in meningitisu.
In fact, the use of gloves is recommended in preparing the solution for infusion.
Zato je pri pripravi raztopine za infundiranje priporočljiva uporaba rokavic.
In fact, the use of gloves is recommended in preparing the solution for infusion.
Zato je pri pripravi raztopine za injiciranje priporočljiva uporaba rokavic.